Effect of Pomanox® on Skin Ageing (POMASKIN) (POMASKIN)

Effect of Two Doses of Pomanox® Pomegranate Extract Consumption on Skin Ageing. Randomized, Parallel, Placebo Controlled and Triple Blind Clinical Trial (POMASKIN).

The state of skin health impacts not only on the general health of individuals, but also on mental health. Ultraviolet radiation (UV) is one of the main external factors that causes skin ageing, producing photo-aging, characterized by multiple alterations in the skin such as the appearance of wrinkles, dryness, erythema, alterations in the pigmentation, inflammation and increased fragility.

Several studies show that polyphenols extracts, including pomegranate extracts, have beneficial effects on various skin characteristics induced by photoaging by modulating internal factors that lead to changes associated with photoaging. Among these internal factors are oxidative stress, glycation stress caused by an accumulation of advances glycation end-products (AGEs), inflammation, and the composition of the intestinal and skin microbiota.

Pomanox® is a polyphenolic extract derived from pomegranate for which antioxidant activity and positive effects on the metabolism of collagen and hyaluronic acid have been shown in previous in vitro studies.

Study Overview

• Status: Not yet recruiting
• Conditions: Skin Ageing
• Intervention / Treatment: Dietary supplement: 367 mg Pomanox group; Dietary supplement: 700 mg Pomanox group; Dietary supplement: Control group

Detailed Description

The hypothesis of the study is that the consumption of Pomanox®P30 will have beneficial effects on skin ageing in humans through the modulation of the metabolism of collagen, hyaluronic acid and the inflammatory system, the inhibition of the production of reactive oxygen species and AGEs, and/or changes in the intestinal and skin microbiota composition.

The main objective of the study is to evaluate the effect of consuming two doses of Pomanox®P30 on hyperpigmented skin spots in humans.

The secondary objectives of the study are to evaluate the effects of consuming two doses of Pomanox®P30 on other parameters related to skin ageing (wrinkles, elasticity, erythema index, hydration, pores, acne and keratin), on different markers of collagen and hyaluronic acid metabolism, oxidative stress, the anti-glycan effect and the inflammatory system, and on the composition of the intestinal and skin microbiota.

A randomized, parallel, placebo-controlled, single-center, triple-blind clinical trial with a 1:1:1 ratio between interventions with 66 participants will be conducted.

Each participant will make 4 visits:

• A pre-selection visit (to check inclusion/exclusion criteria) (V0), and if the eligibility criteria are met,
• 3 study visits during the consumption of the treatments, which will take place on the first day of the study (V1), at 29 days of treatment (V2) and at 85 days of treatment (V3).

• Study Type: Interventional
• Enrollment (Anticipated): 66
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Antoni Caimari, PhD; Phone Number: 0034 977 300 431; Email: antoni.caimari@eurecat.org
• Study Contact Backup: Name: Anna Crescenti, PhD; Phone Number: 977770958; Email: anna.crescenti@eurecat.org

Study Locations

• Spain
  • Reus, Spain, 43204
    • Eurecat
  • Catalonia. Spain
    • Reus, Catalonia. Spain, Spain, 43204
      • Anna Crescenti

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Women aged 30 years or older and 65 years or less.
• Fitzpatrick skin phototype II-IV.
• Read, write and speak Catalan or Spanish.
• Sign the informed consent.

Exclusion Criteria:

• Present any chronic gastrointestinal disease that may interfere with the objectives of the study such as celiac disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome with symptoms in the last 6 months, chronic diarrhea, or having undergone any bariatric surgery procedure.
• Present a chronic disease with clinical manifestation and/or being under pharmacological treatment that may interfere with participation in the study.
• Present values of body mass index ≥ 35 kg/m^2.
• Present a clinical history of active anemia.
• Have consumed or intended to consume during the study treatments, supplements or multivitamin supplements or phytotherapeutic products that interfere with the study treatment (such as retinol or vitamin A, vitamin C, vitamin E, antioxidants, polyphenols, probiotics and prebiotics) up to 30 days before the start of the study intervention.
• Have consumed or intended to consume during the study contraceptive treatments or hormonal therapy up to 30 days before the start of the study intervention.
• Have taken treatment with antibiotics up to 30 days before the start of the study intervention.
• Have taken or intended to take treatments for acne, for photo-ageing or to improve the appearance or condition of the skin (such as chemical peeling, laser therapy, light therapy or hyaluronic acid injection; regular treatment in a facial beauty salon, skin whitening agents) up to 6 months before the start of the study intervention.
• Being a smoker or ex-smoker in the last 6 months before inclusion in the study.
• Consume 2 o more Standard Beverage Units daily or 17 weekly.
• Present allergy and/or intolerance to the study products (such as presenting hypersensitivity to maltodextrin or allergy to pomegranate).
• Being pregnant or intending to become pregnant.
• Being in breastfeeding period.
• Being participating, intending to participate or having participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study.
• Present any skin disease (such as atopic skin, eczema, neurodermatitis, vitiligo or psoriasis) or any skin disorder in the sudy area (such as irritations, moles, scars or macules).
• Have been intensely exposed to the sun or artificial ultraviolet radiations (solarium) in the test area during the 30 days before the start of the study or planning to do so during the study.
• Not being able to follow the guidelines of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 367 mg Pomanox group; One capsule daily with 367 mg of Pomanox®P30 for 12 weeks	Dietary supplement: 367 mg Pomanox group; Treatment with 367 mg Pomanox®P30 during 12 weeks
Experimental: 700 mg Pomanox group; One capsule daily with 700 mg of Pomanox®P30 for 12 weeks	Dietary supplement: 700 mg Pomanox group; Treatment with 700 mg Pomanox®P30 during 12 weeks
Placebo Comparator: Control group; One capsule daily with maltodextrin for 12 weeks	Dietary supplement: Control group; Treatment with maltodextrin during 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in skin melanin index.	Skin melanin index measured by using a Mexameter® MX18.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Age.	The age of the volunteers will be recorded in the case report form.	At day -7 (pre-selection visit).
Change in skin wrinkles.	Skin wrinkles measured using a DermoPrime System.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in skin hydratation.	Skin hydratation measured using a DermoPrime System.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in skin elasticity.	Skin elasticity measured using a Cutometer ®MPA 580.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in skin erythema index.	Skin erythema index measured by using a Mexameter® MX18.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in skin pores.	Skin pores measured using a DermoPrime System.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in skin acne.	Skin acne measured using a DermoPrime System.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in skin keratin.	Skin keratin measured using a DermoPrime System.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in Human Procollagen I N-Terminal Propeptide blood levels.	Serum levels of Human Procollagen I N-Terminal Propeptide will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in Human Procollagen I C-Terminal Propeptide blood levels.	Serum levels of Human Procollagen I C-Terminal Propeptide will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in Metalloproteinase-1 blood levels.	Serum levels of Metalloproteinase will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in hyaluronic acid blood levels.	Serum levels of hyaluronic acid will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in superoxide dismutase activity blood levels.	Serum superoxide dismutase activity will be measured using a colorimetric kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in reduced gluthathione blood levels.	Serum levels of reduced gluthathione will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in pentosidine blood levels.	Serum levels of pentosidine will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in carboxymethyl-lysine blood levels.	Serum levels of carboxymethyl-lysine will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in interleukin-1 alpha blood levels.	Serum levels of interleukin-1 alpha will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in interleukin-6 blood levels.	Serum levels of interleukin-6 will be measured using human ELISA kits.	At day 1 (visit V1) and day 85 (visit 3).
Change in stool microbiota composition.	Total DNA extracted from stool samples will be sequenced on an Ion Torrent platform. It will be analysed the taxonomic profile, alpha diversity and beta diversity.	At day 1 (visit V1) and day 85 (visit 3).
Change in skin microbiota composition.	Total DNA extracted from stool samples will be sequenced on an Ion Torrent platform. It will be analysed the taxonomic profile, alpha diversity and beta diversity.	At day 1 (visit V1) and day 85 (visit 3).
Change in dimethylellagic acid glucuronide urine levels.	Urine levels of dimethylellagic acid glucuronide will be measured by Liquid Chromatography Mass Spectrometry.	At day 1 (visit V1) and day 85 (visit 3).
Change in urolithin A glucuronide urine levels.	Urine levels of urolithin A glucuronide will be measured by Liquid Chromatography Mass Spectrometry.	At day 1 (visit V1) and day 85 (visit 3).
Subject self-assessment quality of the skin.	The quality of the skin of the volunteers will be evaluated subjectively through self-assessment questionnaire of the subjects themselves. This questionnaire will assess the perception of the volunteers on the improvement of their skin in general and on wrinkles, spots, redness, elasticity, hydration, pores and acne. In the questionnaire there will be 5 grades to asses the state: worsened (0), slightly worsened (1), no change (2), slightly improved (3) and improved (4).	At day 29 (visit V2) and day 85 (visit 3).
Height.	Height measured by a standardized method.	At day -7 (pre-selection visit).
Change in body weight.	Body weight measured by a standardized method.	At day -7 (pre-selection visit), day 1 (visit V1, day 29 (visit 2) and day 85 (visit 3).
Change in body mass index.	Weight and height will be combined to report Body Mass Index in kg/m^2.	At day -7 (pre-selection visit), day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in fat mass.	Fat mass measured by TANITA SC 330.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Change in muscle mass.	Muscle mass measured by TANITA SC 330.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Concomitant medication.	Concomitant medication consumed during the study will be recorded in the case report form.	At day -7 (pre-selection visit), day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Dietary supplements consumed.	Dietary supplements consumed during the study will be recorded in the case report form.	At day -7 (pre-selection visit), day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Use of cosmetic treatments.	The use of cosmetic treatments during the study will be recorded in the case report form.	At day -7 (pre-selection visit), day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Exposure to ultraviolet radiation.	Exposure of volunteers to ultraviolet radiation will be recorded in the case report form.	At day -7 (pre-selection visit), day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Products with pomegranate and ellagitannins consumption.	Consumption of products with pomegranate and ellagitannins during the study will be recorded in the case report form.	At day -7 (pre-selection visit), day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Eating habits.	Eating habits of volunteers during the study will be recorded using a food frequency questionnaire.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Physical activity.	Physical activity of volunteers during the study will be recorded using the international physical activity questionnaire.	At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).
Intervention compliance.	The intervention compliance by the volunteers will be assessed by counting the number of remaining capsules and applying the formula (Number of capsules consumed/Number of capsules to consume)x100.	At day 29 (visit 2) and day 85 (visit 3).
Adverse events.	Possible adverse events derived from taking study's products will be recorded in the case report form.	At day 29 (visit 2) and day 85 (visit 3).

Collaborators and Investigators

• Sponsor: Fundació Eurecat
• Collaborators: Euromed, S.A.
• Investigators: Principal Investigator: Antoni Caimari, PhD, Fundació Eurecat

Publications and helpful links

Helpful Links

• Technological Centre of Nutrition and Health. Eurecat_Reus.

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2023
• Primary Completion (Anticipated): August 1, 2023
• Study Completion (Anticipated): August 1, 2023

Study Registration Dates

• First Submitted: April 24, 2023
• First Submitted That Met QC Criteria: April 24, 2023
• First Posted (Estimate): May 4, 2023

Study Record Updates

• Last Update Posted (Estimate): May 4, 2023
• Last Update Submitted That Met QC Criteria: April 24, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Oxidative stress; Hyaluronic acid; Intestinal microbiota; Polyphenols; skin microbiota; Natural extracts; Collagen metabolism; Photoageing; Antiglycan effect; Inflammatory system
• Other Study ID Numbers: POMASKIN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No